About
Antibodies for long term allergy protection
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyFinland
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
57
By Phase
PHASE1: 2
By Status
COMPLETED: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT06037148Lead Sponsor
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
PHASE1Completed
30 participants
Started: Sep 7, 2023 · Completed: Mar 6, 2024
NCT04266028Lead Sponsor
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
PHASE1Completed
27 participants
Started: Feb 11, 2020 · Completed: May 31, 2021
Locations (1)
Headquarters
Espoo, Finland
Map
Loading map...